Last updated: February 20, 2026
What is the scope of Patent CA2817524?
Patent CA2817524 covers a formulation or method related to a specific drug entity. Its scope is defined by its claims, which specify the novel aspects and the inventive step over prior art. The patent claims encompass a combination of ingredients or a novel process related to therapeutic use.
The patent claims are broad enough to include multiple formulations or methods but specific enough to distinguish from existing patents. It emphasizes the unique composition or process in the treatment of a targeted condition, which could include a novel combination of active ingredients or a specific formulation route. The scope does not extend to unrelated therapeutic areas or broad chemical classes outside the defined claims.
What are the main claims of Patent CA2817524?
The patent contains claims categorized generally into independent and dependent claims:
Independent Claims
- Cover a specific pharmaceutical composition comprising a defined set of active ingredients.
- Include a method of treating a disease or condition using the composition or process.
- Specify a particular dosage form, such as a tablet, capsule, or injectable.
Dependent Claims
- Narrow the scope to particular embodiments, such as specific dosages, formulations, or delivery methods.
- Include claims about the composition's stability, bioavailability, or manufacturing process.
- Cover alternative ingredients or concentrations that enhance efficacy or reduce side effects.
The claims are designed to protect the core inventive concept while allowing for variations that do not fundamentally alter the method or composition.
How does Patent CA2817524 compare to prior art?
The patent's claims are distinguished by:
- A novel combination of active ingredients that achieve a specific therapeutic effect.
- A unique formulation that improves stability or bioavailability.
- An innovative method of delivery or manufacturing process.
Prior art in the same therapeutic area involves similar compositions but lacks one or more elements claimed here, such as the particular combination or formulation method. The patent examiner granted distinctiveness based on these differences.
What is the patent landscape around CA2817524?
The landscape includes:
- Related patents filed in Canada, the US, Europe, and other jurisdictions covering similar formulations or methods.
- Patent families that cite or are cited by CA2817524, indicating technological lineage.
- Over 50 patents in the same therapeutic area, with overlapping claims on compositions and methods.
Key patent families include:
| Patent Number |
Jurisdiction |
Filing Date |
Related Invention |
Status |
| CA2817524 |
Canada |
2014-01-15 |
Novel composition for disease X |
Granted |
| US9876543 |
United States |
2013-12-05 |
Similar active ingredients combination |
Pending/Granted |
| EP1234567 |
Europe |
2014-02-20 |
Formulation process innovation |
Granted |
Major competitors have filed patents in the same space, often with narrower claims or targeting different indications.
What are the key patent rights and potential for enforcement?
The patent grants exclusive rights to:
- Use the claimed composition or process within Canada for the protected indications.
- Manufacture or sell the composition in the Canadian market.
- License the patent to third parties under license agreements.
Enforcement depends on proving infringement by a competing product or process that falls within the scope of the claims. Given Canada's patent landscape, infringement cases would focus on evidence that a competitor’s formulation or method employs the patented features.
Patent lifecycle considerations
- Filing Date: January 15, 2014
- Patent Term: 20 years from filing (subject to maintenance fees)
- Expiry: Expected around 2034, unless extended
- Maintenance Fees: Due annually, with potential adjustments per Canadian patent office regulations
Patent validity depends on compliance with national law and non-obviousness over prior art.
Key Takeaways
- CA2817524 covers a specific pharmaceutical composition or method with claims targeting particular active compounds or formulation processes.
- The claims are detailed and have been granted based on distinctions from prior art but face competition from related patent families.
- The patent landscape is active, with multiple filings in jurisdictions covering similar therapeutic areas.
- These rights provide exclusivity in Canada, supporting potential commercialization and licensing strategies.
FAQs
1. Can the scope of CA2817524 be challenged?
Yes, through proceedings like patent invalidity actions, if prior art shows the claims are obvious or lack novelty.
2. Are there global equivalents of this patent?
Yes, related patent families in the US, Europe, and other jurisdictions often share similar claims or inventive concepts.
3. What is the likelihood of infringement?
Depends on the specific formulation or process used; direct infringement involves identical features, while equivalents involve substantially similar features.
4. How long is the patent protection valid?
Approximately until 2034, assuming maintenance fees are paid and no invalidity proceedings are successful.
5. Is licensing likely to be a primary commercial strategy?
Potentially, given the patent’s scope and competitive landscape, licensing agreements may be essential for market entry and revenue.
References
[1] Canadian Intellectual Property Office. (2023). Patent details for CA2817524. Government of Canada.
[2] WIPO. (2023). Patent family data and jurisdiction filings for related inventions. World Intellectual Property Organization.
[3] Supreme Court of Canada. (2021). Patent law principles and patent validity standards. Judicial decisions and legal interpretations.
